aPAP ClearPath

The aPAP ClearPath™ Testing Program

Request a GM-CSF Ab Test Kit through the aPAP ClearPath™ Testing Program

For healthcare providers only. Patients should consult their provider to request testing.

The aPAP ClearPath™ testing program is a no charge, third-party testing program sponsored by Savara Inc. It was established to reduce barriers to GM-CSF autoantibody testing and to provide healthcare professionals and patients with additional knowledge about how testing may be used as a diagnostic resource.

Once you suspect pulmonary alveolar proteinosis (PAP) may be causing your patient’s symptoms, you may request the GM-CSF autoantibody test at no charge. The test is provided without billing the patient, their insurance, or your practice. This simple, accurate, and noninvasive autoantibody blood test may help you confirm or rule out autoimmune PAP (aPAP).1,2

This test is designed to provide results as quantitative anti–GM-CSF concentrations. It comes in a compact package with clear, step-by-step instructions.

aPAP CleaPath Kits

Eligibility Criteria

Reside in the U.S.; Have an abnormal CT Scan; and at least one of the following3, 4, 5
Persistent cough
Persistent cough
Shortness of breath
Shortness of breath
Fatigue

Fatigue

Unintentional changes in weight
Unintentional changes in weight
Chest or back pain
Chest or back pain
Pulmonary disease that is refractory to treatment
Pulmonary disease that is refractory to treatment

You can order the test in 1 of 2 forms*:

Serum-based test:

Serum Test

Blood is drawn through venipuncture into a blood tube, then spun to isolate serum.

Dried Blood Spot test:

Dried blood spot test

Blood is drawn via finger prick, then dropped directly onto a collection card.

As the ordering physician, you will receive quantitative test results via fax and/or secure email within 7 business days of the completed test arriving at the lab. A high concentration of GM-CSF autoantibodies means your patient has aPAP.

Mobile phlebotomy service

Mobile Phlebotomy Service:

If a serum blood draw is not possible in your office, you can order a dried blood spot test or may be able to utilize a mobile phlebotomy service. This service allows patients to have their blood drawn in the comfort of their homes. For more information, contact aPAP@trilliumbio.com or call 1-888-261-2812, option 3.

*aPAP ClearPath testing program is not yet offered in New York State.

How to Collect a Dried Blood Spot Sample Using the ADX100 Card

Provider Test Kit Request Form

All fields required unless otherwise noted.
The NPI number of the authorizing physician is required to order the test.
Name
Optional

Your Order

Please choose the kit(s) and select the quantity you would like to order*:
*aPAP ClearPath testing program is not yet offered in New York State.
Checkboxes

To learn how TrilliumBiO, the certified clinical laboratory that will perform the testing on the patient samples, will use, disclose and protect the patient data you provide as part of ordering the lab test, please review Trillium's HIPAA Notice of Privacy Practices. While the aPAP ClearPath™ testing program is sponsored by Savara Inc., testing is performed by TrilliumBiO, a CLIA-certified laboratory.​ Savara receives de-identified patient data from this program, but at no time does Savara receive patient-identifiable information. Additionally, Savara will not receive any contact information about the ordering healthcare professional.​Testing can only be ordered by healthcare professionals in the U.S. for patients that meet certain eligibility criteria.​ Use of the test and results should in no way influence or interference with the healthcare professional’s independent clinical judgment or how to manage or what therapy to treat with.​The healthcare professional, in consultation with the patient, should consider all potential management options. Healthcare professionals and patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Savara product.

References: 1. McCarthy C, Kokosi M, Bonella F. Shaping the future of an ultra-rare disease: unmet needs in the diagnosis and treatment of pulmonary alveolar proteinosis. Curr Opin Pulm Med. 2019;25(5):450-458. doi:10.1097/MCP.0000000000000601 2. Ataya A, Knight V, Carey BC, Lee E, Tarling EJ, Wang T. The role of GM-CSF autoantibodies in infection and autoimmune pulmonary alveolar proteinosis: a concise review. Front Immunol. 2021;12:752856. doi:10.3389/fimmu.2021.752856 3. McCarthy C, Avetisyan R, Carey BC, Chalk C, Trapnell BC. Prevalence and healthcare burden of pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2018;13(1):129-133. doi:10.1186/s13023018-0846-y 4. Miyashita K, Hozumi H, Inoue Y, Suzuki T, Suda T. Nationwide survey of adult patients with pulmonary alveolar proteinosis using the National Database of designated intractable diseases of Japan. Respir Investig. 2023;61(3):364-370. doi:10.1016/j.resinv.2023.02.011 5. aPAP patient journey & qualitative segmentation; final report. Savara Inc.; 2023; Langhorne, PA.